Literature DB >> 16195602

An inhibitor of glucosylceramide synthase inhibits the human enzyme, but not enzymes from other organisms.

Inga Hillig1, Dirk Warnecke, Ernst Heinz.   

Abstract

Specific inhibitors of glucosylceramide biosynthesis are used as drugs for the treatment of some human diseases correlated to glycosphingolipid metabolism. The target of the presently available inhibitors is the human glucosylceramide synthase (GCS), but effects on enzymes from other organisms have not been studied. We expressed cDNAs encoding GCS enzymes from lower animals, plants, fungi, and bacteria in the yeast P. pastoris. In vitro GCS assays with the GCS inhibitor D-threo-1-(3',4'-ethylenedioxy)phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol showed that this inhibitor did not affect non-human GCS enzymes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16195602     DOI: 10.1271/bbb.69.1782

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  5 in total

Review 1.  Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.

Authors:  Yong-Yu Liu; Ronald A Hill; Yu-Teh Li
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 2.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

3.  Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.

Authors:  Amar Ghisaidoobe; Pieter Bikker; Arjan C J de Bruijn; Frithjof D Godschalk; Eva Rogaar; Marieke C Guijt; Peter Hagens; Jerre M Halma; Steven M Van't Hart; Stijn B Luitjens; Vincent H S van Rixel; Mark Wijzenbroek; Thor Zweegers; Wilma E Donker-Koopman; Anneke Strijland; Rolf Boot; Gijs van der Marel; Herman S Overkleeft; Johannes M F G Aerts; Richard J B H N van den Berg
Journal:  ACS Med Chem Lett       Date:  2010-12-02       Impact factor: 4.345

4.  Fungal glucosylceramides: from structural components to biologically active targets of new antimicrobials.

Authors:  Leonardo Nimrichter; Marcio L Rodrigues
Journal:  Front Microbiol       Date:  2011-10-20       Impact factor: 5.640

5.  Species-Specific Differences in the Susceptibility of Fungi to the Antifungal Protein AFP Depend on C-3 Saturation of Glycosylceramides.

Authors:  Norman Paege; Dirk Warnecke; Simone Zäuner; Silke Hagen; Ana Rodrigues; Birgit Baumann; Melanie Thiess; Sascha Jung; Vera Meyer
Journal:  mSphere       Date:  2019-12-11       Impact factor: 4.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.